Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05124639
Other study ID # PJT-169163
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 6, 2022
Est. completion date December 21, 2026

Study information

Verified date May 2024
Source Université de Sherbrooke
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background. Self-management support is a complementary approach to treatment that aims to educate participants on the nature of anxiety and to improve their strategies to manage symptoms and well-being, thus presenting the potential to enhance recovery, improve outcomes, reduce recurrence rates and lower health care costs. There is limited evidence to support the effectiveness of group self-management support for anxiety disorders in community-based care. Objectives. This study aims at examining the effectiveness of a virtual group self-management support program (SMS) for anxiety disorders as an add-on to treatment-as-usual (TAU) in community-based care settings. We will also assess the incremental cost/effectiveness ratio and the implementability of the intervention. Methods. The trial is a pragmatic randomized controlled trial with a pre-treatment, post-treatment (4-month post-randomization), and follow-ups at 8, 12 and 24-months. Intervention. The experimental condition will consist of a 10-week SMS program for anxiety disorders in addition to TAU. The control condition will receive TAU without restrictions for anxiety disorders. Inclusion criteria will comprise being 18 years old or older, French-speaking, and presenting symptoms of anxiety disorders based on self-reported validated assessment scales. Patients will be recruited in the province of Quebec (Canada). Outcome measures: The primary outcome measure is the Beck Anxiety Inventory (BAI). The secondary outcome measures include self-reported instruments for anxiety and depressive symptoms, recovery, self-management, quality of life, and service utilisation. Statistical analysis: Intention-to-treat analysis. A mixed effects regression model will be used to account for between and within-subject variations in the analysis of the longitudinal effects of the intervention. Expected outcomes. The rigorous evaluation of the SMS intervention in the real world will provide information to decision makers, health care managers, clinicians and patients regarding the added value of group SMS for patients with anxiety disorders. Widespread implementation of this intervention could lead to more efficient mental health care services, to better long-term outcomes and to a significant reduction in the extensive social and economic burden of anxiety disorders.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 414
Est. completion date December 21, 2026
Est. primary completion date March 16, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - (1) aged 18 and over, - (2) fluent in spoken and written French, - (3) presence of symptoms of anxiety disorders based on self-reported validated assessment scales and semi-structured assessment interview, - (4) access to a computer or tablet connected to the internet with microphone and video camera Exclusion Criteria: - (1) previous enrolment in the SMS intervention provided by Relief - (2) active suicidal intentions, - (3) severe depressive symptoms, - (4) active substance-related and addictive disorder, - (5) cognitive impairment

Study Design


Intervention

Behavioral:
Group self-management support program for anxiety disorders
The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.

Locations

Country Name City State
Canada Université de Sherbrooke Sherbrooke Quebec

Sponsors (3)

Lead Sponsor Collaborator
Université de Sherbrooke Canadian Institutes of Health Research (CIHR), Relief

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Gross Cohesion Scale During the 10-week SMS program, after sessions 3 and 8 (for experimental arm participants)
Other Working Alliance Inventory During the 10-week SMS program, after sessions 3 and 8 (for experimental arm participants)
Primary Change in Beck Anxiety Inventory (BAI) Baseline and post-treatment (4-month post-randomization)
Secondary Change in Beck Anxiety Inventory Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups
Secondary Change in Generalised Anxiety Disorder-7 Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups
Secondary Change in Patient Health Questionnaire-9 Baseline, post-treatment,12-month and 24-month post-randomization follow-ups
Secondary Change in Recovery Assessment Scale - Revised Baseline, post-treatment,12-month and 24-month post-randomization follow-ups
Secondary Change in Mental Health Self-Management Questionnaire Baseline, post-treatment,12-month and 24-month post-randomization follow-ups
Secondary Change in Assessment of Quality of Life - 6 Dimensions Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups
Secondary Change in Health care use and indirect costs Health care costs for other mental health consultations (e.g. type of professional, duration, costs), psychotherapy experience (including CBT) and psychotropic medication. Baseline, post-treatment, and 8-month, 12-month, 24-month post-randomization follow-ups
Secondary Change in Administrative databases records Data will be obtained from provincial administrative databases for medical and biopsychosocial services, hospitalization's registry, and medication data. Starting 12 months prior to participant enrolment up to the 24-month post-randomization follow-up
See also
  Status Clinical Trial Phase
Terminated NCT03420456 - Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Withdrawn NCT02382224 - Worry Exposure for Generalized Anxiety Disorder N/A
Completed NCT02306356 - Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting N/A
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT01958788 - Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder N/A
Completed NCT01681329 - Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder N/A
Completed NCT01342120 - PHARMO Institute Seroquel Safety Study N/A
Completed NCT01337713 - Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD) N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT01971203 - Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat N/A
Completed NCT00961298 - An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Phase 4
Completed NCT01203293 - Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector Phase 1
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00744627 - Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults. Phase 3
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00537615 - An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers Phase 1
Completed NCT00515242 - Therapeutic Massage for Generalized Anxiety Disorder Phase 1/Phase 2
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00368745 - Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use. Phase 3